Improving Lives Through

Innovative Diagnostic Solutions

AXIM is an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics solutions

Improving Lives Through

Innovative Diagnostic Solutions

AXIM is an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics solutions

COVID-19 TESTING

AXIM Biotech has developed a rapid (10-minute) serological diagnostic test that detects SARS-CoV-2 neutralizing antibodies (Nabs) which are the antibodies needed to fight COVID-19 within the body.

AXIM EYE

AXIM looks to assist doctors in diagnosing dry eye disease (DED) faster and more efficiently than alternative methods.  

CANCER dIAGNOSTICS

AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer

The Latest On Our Research

Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing the landscape of diagnosis of SARS-CoV-2 (COVID-19), dry eye disease (DED) and Oncological indications. AXIM’s COVID-19 neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and ophthalmological conditions such as DED.

AXIM Biotechnologies CEO Issues Letter to Shareholders

  Summary: AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system Plans to address largely underserved DED diagnosis market with patent pending tear collection method and approved tests, supported by world-class DED...

read more